skip to content
Thank you for visiting First Coast Service Options' Medicare provider website. This website is intended exclusively for Medicare providers and health care industry professionals to find the latest Medicare news and information affecting the provider community.
To enable us to present you with customized content that focuses on your area of interest, please select your preferences below:
Select which best describes you:
Select your location:
Select your line of business:
This website provides information and news about the Medicare program for health care professionals only. All communication and issues regarding your Medicare benefits are handled directly by Medicare and not through this website. For the most comprehensive experience, we encourage you to visit Medicare.gov or call 1-800-MEDICARE. In the event your provider fails to submit your Medicare claim, please view these resources for claim assistance.
Join eNews       En Español
Text Size:
YouTube LinkedIn Email Print
Send a link to this page
[Multiple email adresses must be separated by a semicolon.]
Last Modified: 4/28/2022 Location: FL, PR, USVI Business: Part B

COVID-19 vaccine and monoclonal antibody billing for Part B providers

This article will assist Medicare Part B providers with proper billing relating to Coronavirus (COVID-19) vaccine and monoclonal antibody infusion. Beneficiary coinsurance and deductible are waived.

How to bill for COVID-19 vaccines and monoclonal antibodies

For billing single claims for COVID-19 vaccines and monoclonal antibodies, follow the instructions in the article below.
For roster billing and centralized billing refer to the Medicare billing for COVID-19 vaccine shot administration external link page.
When COVID-19 vaccine and monoclonal antibody doses are provided by the government without charge, only bill for the vaccine administration. Don't include the vaccine codes on the claim when the vaccines are free.
If the patient is enrolled in a Medicare Advantage (MA) plan, submit your COVID-19 vaccine and monoclonal antibody infusion claims to Original Medicare in 2020 and 2021. On or after January 1, 2022, claims for vaccine or mAb administrations for Medicare Advantage enrollees should be submitted to the Medicare Advantage plan. For services provided to Medicare Advantage enrollees on or after January 1, 2022, contact the Medicare Advantage for guidance on coverage and billing.

COVID-19 vaccines and administration

Code
Description
Labeler name
Vaccine/procedure name***
Effective date
91300*
SARSCOV2 VAC 30MCG/0.3ML IM
Pfizer
Pfizer-Biontech COVID-19 Vaccine
12/11/2020
0001A
ADM SARSCOV2 30MCG/0.3ML 1ST
Pfizer
Pfizer-Biontech COVID-19 Vaccine Administration – First Dose
12/11/2020
0002A
ADM SARSCOV2 30MCG/0.3ML 2ND
Pfizer
Pfizer-Biontech COVID-19 Vaccine Administration – Second Dose
12/11/2020
0003A
ADM SARSCOV2 30MCG/0.3ML 3RD
Pfizer
Pfizer-Biontech COVID-19 Vaccine Administration – Third Dose
08/12/2021
0004A
ADM SARSCOV2 30MCG/0.3ML BST
Pfizer
Pfizer-Biontech COVID-19 Vaccine Administration – Booster
09/22/2021
91301*
SARSCOV2 VAC 100MCG/0.5ML IM
Moderna
Moderna COVID-19 Vaccine
12/18/2020
0011A
ADM SARSCOV2 100MCG/0.5ML1ST
Moderna
Moderna COVID-19 Vaccine Administration – First Dose
12/18/2020
0012A
ADM SARSCOV2 100MCG/0.5ML2ND
Moderna
Moderna COVID-19 Vaccine Administration – Second Dose
12/18/2020
0013A
ADM SARSCOV2 100MCG/0.5ML3RD
Moderna
Moderna COVID-19 Vaccine Administration – Third Dose
08/12/2021
91303*
SARSCOV2 VAC AD26 .5ML IM
Janssen
Janssen COVID-19 Vaccine
02/27/2021
0031A
ADM SARSCOV2 VAC AD26 .5ML
Janssen
Janssen COVID-19 Vaccine Administration – First Dose
02/27/2021
0034A
ADM SARSCOV2 VAC AD26 .5ML B
Janssen
Janssen COVID-19 Vaccine Administration - Booster
10/20/2021
91305*
SARSCOV2 VAC 30 MCG TRS-SUCR
Pfizer
Pfizer-BioNTech COVID-19 Vaccine Pre-Diluted (Gray Cap)
01/03/2022
0051A
ADM SARSCV2 30MCG TRS-SUCR 1
Pfizer
Pfizer-BioNTech COVID-19 Vaccine Pre-Diluted (Gray Cap) Administration - First dose
01/03/2022
0052A
ADM SARSCV2 30MCG TRS-SUCR 2
Pfizer
Pfizer-BioNTech COVID-19 Vaccine Pre-Diluted (Gray Cap) Administration - Second dose
01/03/2022
0053A
ADM SARSCV2 30MCG TRS-SUCR 3
Pfizer
Pfizer-BioNTech COVID-19 Vaccine Pre-Diluted (Gray Cap) Administration - Third dose
01/03/2022
0054A
ADM SARSCV2 30MCG TRS-SUCR B
Pfizer
Pfizer-BioNTech COVID-19 Vaccine Pre-Diluted (Gray Cap) Administration - Booster
01/03/2022
91306*
SARSCOV2 VAC 50MCG/0.25ML IM
Moderna
Moderna COVID-19 Vaccine (Low Dose)
10/20/2021
0064A
ADM SARSCOV2 50MCG/0.25MLBST
Moderna
Moderna COVID-19 Vaccine (Low Dose) Administration - Booster
10/20/2021
91307*
SARSCOV2 VAC 10 MCG TRS-SUCR
Pfizer
Pfizer-BioNTech COVID-19 Pediatric Vaccine
10/29/2021
0071A
ADM SARSCV2 10MCG TRS-SUCR 1
Pfizer
Pfizer-BioNTech COVID-19 Pediatric Vaccine - Administration - First dose
10/29/2021
0072A
ADM SARSCV2 10MCG TRS-SUCR 2
Pfizer
Pfizer-BioNTech COVID-19 Pediatric Vaccine - Administration - Second dose
10/29/2021
0073A
ADM SARSCV2 10MCG TRS-SUCR 3
Pfizer
Pfizer-BioNTech COVID-19 Pediatric Vaccine (Orange Cap) - Administration - Third dose
01/03/2022
91309*
SARSCOV2 VAC 50MCG/0.5ML IM
Moderna
Moderna COVID-19 Vaccine (Blue Cap) 50MCG/0.5ML (Booster)
03/29/2022
0094A
ADM SARSCOV2 50MCG/0.5 MLBST
Moderna
Moderna COVID-19 Vaccine (Blue Cap) 50MCG/0.5ML Administration - Booster
03/29/2022
M0201**
COVID-19 vaccine home admin
N/A
COVID-19 vaccine administration inside a patient’s home; reported only once per individual home per date of service when only COVID-19 vaccine administration is performed at the patient’s home
06/08/2021
*Providers should not bill for the product if they received it for free.
**Billable only in places of service 04, 06, 09, 12, 13, 14, 16, 19, 22, 33, 54, 55, 56, and 60. For additional billing information on M0201, review CMS’ infographic on Medicare payment for COVID-19 vaccine administration in the home external pdf file.
***For information on dosing intervals, refer to the CDC article U.S. COVID-19 Vaccine Product Information external link.
Providers can submit claims using the following claim example:
Claim should include the proper billing of the ICD-10 in item 21:
Z23 - Encounter for immunization
Report the proper date of service
Report the proper place of service
Use the applicable CPT or HCPCs code
The diagnosis pointer should be used to indicate the primary diagnosis on the claim form

Monoclonal antibodies and administration

Code
Description
Labeler name
Vaccine/procedure name
Effective date
Q0220*
Tixagev and cilgav, 300mg
AstraZeneca
Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available COVID-19 vaccine is not recommended due to a history of severe adverse reaction to a COVID-19 vaccine(s) and/or COVID-19 vaccine component(s), 300 mg
12/08/2021
Q0221*
Tixagev and cilgav, 600mg
AstraZeneca
Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available COVID-19 vaccine is not recommended due to a history of severe adverse reaction to a COVID-19 vaccine(s) and/or COVID-19 vaccine component(s), 600 mg
02/24/2022
M0220
Tixagev and cilgav inj
AstraZeneca
Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available COVID-19 vaccine is not recommended due to a history of severe adverse reaction to a COVID-19 vaccine(s) and/or COVID-19 vaccine component(s), includes injection and post administration monitoring
12/08/2021
M0221
Tixagev and cilgav inj hm
AstraZeneca
Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available COVID-19 vaccine is not recommended due to a history of severe adverse reaction to a COVID-19 vaccine(s) and/or COVID-19 vaccine component(s), includes injection and post administration monitoring in the home or residence; this includes a beneficiary’s home that has been made provider-based to the hospital during the COVID-19 public health emergency
12/08/2021
Q0222*
Bebtelovimab 175 mg
Eli Lilly
Injection, bebtelovimab, 175 mg
02/11/2022
M0222
Bebtelovimab injection
Eli Lilly
Intravenous injection, bebtelovimab, includes injection and post administration monitoring
02/11/2022
M0223
Bebtelovimab injection home
Eli Lilly
Intravenous injection, bebtelovimab, includes injection and post administration monitoring in the home or residence; this includes a beneficiary’s home that has been made provider-based to the hospital during the COVID-19 public health emergency
02/11/2022
Q0239*
bamlanivimab-xxxx
Eli Lilly
Injection, bamlanivimab, 700 mg
11/10/2020 – 04/16/2021
M0239
bamlanivimab-xxxx infusion
Eli Lilly
Intravenous infusion, bamlanivimab-xxxx, includes infusion and post administration monitoring
11/10/2020 – 04/16/2021
Q0240*
Casirivi and imdevi 600mg
Regeneron
Injection, casirivimab and imdevimab, 600 mg
07/30/2021
M0240
Casiri and imdev repeat
Regeneron
Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring, subsequent repeat doses
07/30/2021
M0241
Casiri and imdev repeat hm
Regeneron
Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring in the home or residence, this includes a beneficiary's home that has been made provider-based to the hospital during the COVID-19 public health emergency, subsequent repeat doses
07/30/2021
Q0243*
casirivimab and imdevimab
Regeneron
Injection, casirivimab and imdevimab, 2400 mg
11/21/2020
M0243
Casirivi and imdevi inj
Regeneron
Intravenous infusion or subcuteaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring
11/21/2020
Q0244*
casirivi and imdevi 1200 mg
Regeneron
Injection, casirivimab and imdevimab, 1200 mg
06/03/2021
M0244
Casirivi and imdevi inj hm
Regeneron
Intravenous infusion or subcuteaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring in the home or residence; this includes a beneficiary’s home that has been made provider-based to the hospital during the COVID-19 public health emergency
05/06/2021
Q0245*
bamlanivimab and etesevima
Eli Lilly
Injection, bamlanivimab and etesevimab, 2100 mg
02/09/2021
M0245
bamlan and etesev infusion
Eli Lilly
intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring
02/09/2021
M0246
bamlan and etesev infus home
Eli Lilly
Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring in the home or residence; this includes a beneficiary’s home that has been made provider-based to the hospital during the COVID-19 public health emergency
05/06/2021
Q0247**
sotrovimab
GSK
Injection, sotrovimab, 500 mg
05/26/2021
M0247
sotrovimab infusion
GSK
Intravenous infusion, sotrovimab, includes infusion and post administration monitoring
05/26/2021
M0248
sotrovimab inf, home admin
GSK
Intravenous infusion, sotrovimab, includes infusion and post administration monitoring in the home or residence; this includes a beneficiary’s home that has been made provider-based to the hospital during the COVID-19 public health emergency
05/26/2021
Q0249**
Tocilizumab for COVID-19
Genentech
Injection, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with COVID-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) only, 1 mg
06/24/2021
M0249
Adm Tocilizu COVID-19 1st
Genentech
Intravenous infusion, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with COVID-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) only, includes infusion and post administration monitoring, first dose
06/24/2021
M0250
Adm Tocilizu COVID-19 2nd
Genentech
Intravenous infusion, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with COVID-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) only, includes infusion and post administration monitoring, second dose
06/24/2021
*Providers should not bill for the product if they received it for free.
**The government won’t provide this drug for free.
Providers can submit claims using the following claim example:
Claim should include the proper billing of the ICD-10 in item 21:
Use appropriate diagnosis coded to highest level of specificity
U071 – use as appropriate
Report the proper date of service
Report the proper place of service
Use the applicable CPT or HCPCs code
The diagnosis pointer should be used to indicate the primary diagnosis on the claim form
Report the charge amount for each line item
Click here for information on billing these services through roster billing.

References

CDC: COVID-19 Vaccination Communication Toolkit external link for medical centers, clinics, and clinicians
FDA: COVID-19 Vaccines external link webpage
First Coast Service Options (First Coast) strives to ensure that the information available on our provider website is accurate, detailed, and current. Therefore, this is a dynamic site and its content changes daily. It is best to access the site to ensure you have the most current information rather than printing articles or forms that may become obsolete without notice.